Researchers have identified Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibition as a promising new therapeutic target for chronic inflammatory skin diseases (ISDs). Studies show this approach can prevent keratinocyte cell death and reduce skin inflammation in preclinical models of conditions like lichen planus (LP) and cutaneous lupus erythematosus (CLE).
LP and CLE significantly impact quality of life. Both are linked to type 1 immune responses and characterized by increased keratinocyte cell death. RIPK1 plays a crucial role in programmed cell death and inflammation, making it a key focus.
Analysis of ISD samples revealed significantly upregulated markers of apoptosis and necroptosis in LP and CLE lesions, supporting the role of dysregulated cell death in disease. In preclinical tests, a novel RIPK1 inhibitor, eclitasertib, demonstrated protective effects against systemic inflammation in a mouse model.
Furthermore, eclitasertib treatment prevented keratinocyte cell death in reconstructed human epidermis, normalized epidermal structure, and reduced the release of pro-inflammatory cytokines. Ex vivo cultures of LP and CLE skin biopsies also showed a downregulation of disease-specific genes and inflammatory pathways with eclitasertib treatment.
These findings suggest RIPK1 inhibition simultaneously addresses two central pathological processes in type 1 mediated chronic ISDs: epidermal cell death and immune-driven inflammation. While promising, further clinical trials are necessary to confirm safety and efficacy in human patients.